The short answer
Chromium may add to insulin’s glucose-lowering effect, so supplement use warrants an individual monitoring plan. An insulin-glulisine-specific risk or chromium requirement has not been established.
What this answer covers
Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium.
- Supplement or preparation
- Chromium
- Medication ingredient
- insulin glulisine, human
Why the precaution applies
NIH guidance cautions that chromium may increase glucose-lowering effects when combined with insulin. Apidra calls for review when glucose-active treatments change. This is a conditional precaution, not a measured interaction rate.
The direct drug trial used glipizide
A chromium-picolinate study improved insulin sensitivity and glucose control in people taking glipizide GITS. Glipizide stimulates insulin secretion and is not injected insulin glulisine. That study cannot quantify the risk for this pair.
No extra chromium need follows
The trial does not show that insulin glulisine depletes chromium or that every insulin user should supplement. Chromium form, elemental dose and overlapping products need review, particularly with high-dose preparations.
Monitoring is more useful than assumed spacing
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. No hour-based gap has been shown to remove chromium’s possible glucose effect.
Evidence and practical considerations
Side effects & toxicity
Federal insulin/chromium precaution supports monitoring, while the inspected drug trial is glipizide, not insulin glulisine; no exact incidence or nutritional requirement.
- Exact scope
- Trivalent oral chromium supplements; picolinate trial evidence does not represent every salt or industrial hexavalent chromium. with Insulin glulisine human RxCUI400008 IN; Apidra product and routes.
- Medication form and route
- injected insulin glulisine; oral supplement
What remains uncertain
- No exact-pair event rate or universal insulin adjustment established.
Factors that may matter: Product; Dose; Meal pattern; Other glucose-active treatments.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes prescribed Apidra
Hypoglycemia can be severe. Niacin may decrease glucose-lowering effect. Changed glucose-active treatment may require more monitoring and clinician-directed dose review. Subcutaneous mealtime injection within15minutes before or20minutes after meal start.
How this applies: Exact insulin glulisine product and routes independently checked.
General insulin risks do not establish an herb-specific adverse-event rate. Other insulins and premixes have different action and meal instructions.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes.
Chromium group had improved insulin sensitivity and glycemic control; the abstract does not provide a hypoglycemia event rate.
How this applies: Indirect for exact insulin glulisine; source medication and supplement formulation are preserved.
37initially evaluated; randomized groups described as17chromium and12placebo. One chromium salt and XL regimen, not a dose or timing requirement. This does not establish an exact insulin-glulisine interaction.
Source 3: federal health guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Chromium may add to glucose-lowering effects of diabetes medicines; clinical benefit is inconsistent. No established glipizide-induced requirement.
How this applies: Indirect for exact insulin glulisine; source medication and supplement formulation are preserved.
Not toxic industrial hexavalent chromium; guidance is not a quantified exact-pair trial. This does not establish an exact insulin-glulisine interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glulisine article with independently inspected Apidra label and source-specific clinical limits. | |
| Research summary published |
Article revision: 15ef8be30b1feac1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.